Company intelligence / Profile preview

Bioglane

Barcelona, Catalonia, Spainpmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

Bioglane was a spin-off from the Spanish Research Council (CSIC) based at Barcelona Science Park. It pioneered the development and commercialization of natural iminosugars—bioactive small molecules with demonstrated benefits in weight management and gut microbiota modulation. The company received recognition such as the Biotechnology Expoquimia R+D+I Award but does not appear to be currently active or developing pharmaceutical products.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

Collaboration with CSIC; no major pharma partnerships identified

Beyond the preview

Go deeper on Bioglane.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioglane.

Explore the full profile